Calidi Biotherapeutics Highlights Financial Progress
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has recently made significant strides in its financial strategy, declaring an impressive cash balance of approximately $9.6 million as of the year-end. This announcement underscores the company's commitment to advancing its innovative virotherapy platforms while ensuring a strong foundation for its clinical and operational goals.
Termination of Standby Equity Purchase Agreement
In a strategic move, Calidi has officially terminated its Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., an affiliate of Yorkville Advisors, effective immediately. This decision, made in late January, stems from the company's robust fundraising success, which includes proceeds from its At-The-Market Offering Agreement (ATM). With a renewed focus and enhanced cash reserves, Calidi is shedding potential overhangs on its stock and reinforcing its aim to enhance shareholder value.
Understanding the SEPA Structure
The SEPA, which was initially executed in December 2023 and modified in January 2024, permitted Calidi to sell up to $25 million of common stock over three years, contingent on specific trading volume and ownership limitations. Notably, the shares tied to this agreement have not been registered, and Calidi did not capitalize on the option to sell these shares.
Successful Fundraising Efforts
In a remarkable show of support from the investment community, Calidi secured $9.5 million in gross proceeds during the fourth quarter of 2024 through two successful public offerings. Additionally, the company raised $2.0 million from warrant exercises and $3.1 million through its ATM offering. Following this trend, a new public offering launched in January 2025 successfully generated an extra $4.25 million in gross proceeds, contributing to the company's financial resilience. These fundraising efforts have bolstered Calidi's cash position, positioning it to address its capital needs effectively without reliance on the SEPA framework.
CEO Remarks on Financial Developments
Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics, emphasized the importance of terminating the SEPA, viewing it as a milestone in the company's fiscal strategy. Camaisa expressed confidence in Calidi's fortified financial standing, stating that the recent fundraising achievements enable the company to redirect its focus toward clinical and operational objectives. This shift not only enhances shareholder confidence but also reinforces Calidi's leadership in both targeted systemic and localized antitumor virotherapies.
Advancements in Virotherapy Development
Calidi Biotherapeutics continues to make remarkable advancements in its virotherapy platforms. One of the recent milestones for the company includes the acceptance of an abstract for its systemic platform, known as RTNova enveloped virotherapies, for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting. Additionally, Calidi achieved IND clearance from the FDA for a Phase 1b/2 trial of CLD-101 focused on treating high-grade gliomas, with plans to commence patient enrollment soon. These groundbreaking developments highlight Calidi’s commitment to pioneering solutions in oncology.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) operates as a clinical-stage immuno-oncology company dedicated to employing proprietary technology designed to empower the immune system in its fight against cancer. With innovative stem cell-based platforms that utilize powerful allogeneic stem cells, Calidi aims to deliver oncolytic viruses effectively, targeting various oncology indications, including high-grade gliomas and solid tumors. The company’s unique, off-the-shelf, universal cell-based delivery systems have been developed to enhance the efficacy of oncolytic viruses, thereby optimizing patient safety and potentially preventing metastatic disease.
Frequently Asked Questions
What recent financial developments has Calidi Biotherapeutics reported?
Calidi Biotherapeutics reported a cash balance of approximately $9.6 million as of December 31, 2024, following successful fundraising efforts.
Why did Calidi terminate the Standby Equity Purchase Agreement?
The termination of the SEPA was a strategic decision influenced by the company’s enhanced cash position and recent fundraising successes, allowing for a focus on growth without the constraints of the agreement.
How much capital has Calidi raised recently?
In the last quarter of 2024, Calidi raised $9.5 million through public offerings, along with an additional $4.25 million from a recent offering in January 2025.
What are Calidi's future plans in clinical development?
Calidi plans to begin patient enrollment for a Phase 1b/2 trial of CLD-101, aimed at treating high-grade gliomas, building on its recent regulatory clearance.
What distinguishes Calidi's approach to cancer treatment?
Calidi utilizes proprietary stem cell-based platforms to deliver oncolytic viruses which can enhance the efficacy and safety of cancer treatments, representing a novel approach to immuno-oncology.
